Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.
McNeel, D. G. (2016, November 15). TCR diversity - a universal cancer immunotherapy biomarker. Journal for ImmunoTherapy of Cancer. BioMed Central Ltd. https://doi.org/10.1186/s40425-016-0175-4
Mendeley helps you to discover research relevant for your work.